Figure 5

Kaplan-Meier estimates of progression-free survival according to the BCAT1 expression level and MGMT promoter methylation status. (A) In all patients, there was a significant difference in PFS between low and high BCAT1 expression tumors (median, 15.2 [95% CI, 12.1–15.2] vs 7.4 [95% CI, 3.5–12.2] months; P = 0.0010, logrank test). (B) The patients with IDH1-wildtype GBMs also showed a significant difference in PFS between low and high BCAT1expression tumors (median, 12.8 [95% CI, 10.8–15.2] vs 7.4 [95% CI, 3.5–12.2] months; P = 0.0059, logrank test). (C,D) In terms of the MGMT promoter methylation status, PFS was significantly longer in the positive tumors than negative ones (median, 18.4 [95% CI, 12.2–18.4] vs 9.5 [95% CI, 7.6–12.1] months; P = 0.0348, logrank test) in all patients, but, among patients with IDH1-wildtype GBMs, there was no significant difference between patients with positive and negative MGMT promoter methylation (median, 15.2 [95% CI, 12.2–18.4] vs 9.5 [95% CI, 7.6–12.1] months; P = 0.0582, logrank test).